| | Family Health | Baby Health
First-Trimester Down Syndrome Screening: NIPT, Combined Test, and Diagnostic Options
Prenatal screening for trisomy 21 (Down syndrome) before 14 weeks includes non-invasive and invasive options.
Screening Tests (Risk Assessment, Not Diagnostic)
1. Combined First-Trimester Screening (11–14 weeks)
- Maternal serum: PAPP-A (↓ in trisomy 21), free β-hCG (↑).
- Nuchal translucency (NT) ultrasound: Increased NT (>3.5 mm or >95th percentile) correlates with aneuploidy and structural defects.
- Detection rate: ~85–90% for 5% false-positive rate.
2. Cell-Free DNA (cfDNA) / NIPT (from 10 weeks)
- Analyzes placental DNA in maternal blood. Detects trisomies 21, 18, 13, sex chromosome aneuploidies.
- Detection rate for trisomy 21: >99%; false-positive rate <0.1%.
- Not diagnostic—positive results require confirmatory invasive testing.
Diagnostic Tests (Definitive)
- Chorionic villus sampling (CVS): 10–13 weeks. Transcervical/transabdominal placental biopsy. Miscarriage risk ~0.2–0.5%.
- Amniocentesis: ≥15 weeks. Amniotic fluid karyotype/CMA. Miscarriage risk ~0.1–0.3%.
Counseling Points
Screening is optional. Positive screen ≠ diagnosis. NIPT has higher sensitivity/specificity but does not detect all chromosomal abnormalities (e.g., balanced translocations, some mosaicism). Diagnostic testing provides certainty but carries procedure risk. Shared decision-making with genetic counseling is standard.
Baby Health - Related Articles
- Caffeine and Pregnancy: Risks and Safe Consumption
- Understanding Milk Allergy in Babies: Symptoms, Causes & Treatment
- Managing Infant Fevers: Safe Home Remedies & When to Seek Help
- Understanding Heart Sounds: Instruments & What They Reveal
- Homemade Pedialyte: A Simple DIY Recipe for Kids' Hydration
- Understanding Human Conception: A Comprehensive Guide
- Kernicterus Prevention: Protecting Your Newborn from Brain Damage
